Collecting this in one place because it comes up every few weeks and the answer is always assembled from scratch. It is about cross-border ordering, and it is deliberately narrow — everything I am not confident about is marked as such.
The variables that decide how a cross-border order goes are declaration wording, the destination country's import rules for prescription medicines, and whether the shipment looks commercial. Personal-import allowances exist in some jurisdictions and not in others, and where they exist they are usually conditional on a prescription and a quantity limit. The failure mode is normally a seizure notice rather than anything worse, and a reshipment policy is the thing worth confirming before ordering rather than after.
Cold chain is the underrated risk on long routes. A shipment held at a border for a week has had a temperature excursion whether or not it arrives.
What would genuinely help is knowing which of the variables in a cross-border order actually determine the outcome, and which are superstition. If the honest answer is that nobody knows, that is a useful answer and I would rather have it.
AussieAnna said:The variables that decide how a cross-border order goes are declaration wording, the destination country's import rules for prescription medicines,…
Agreed, and light exposure is a real but secondary factor. Keep it in the carton; do not build a protocol around it.
AussieAnna said:The variables that decide how a cross-border order goes are declaration wording, the destination country's import rules for prescription medicines,…
Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. Import rules are jurisdiction-specific and this board keeps giving US-shaped answers to non-US questions. What is a personal-import allowance in one country is a controlled-import offence in another.
That is the short version; the long version is somebody else's post.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsShort answer first, then the reasoning. Freezing is the one to avoid, and freeze-thaw more so. Ice-crystal formation and the concentration changes at the phase boundary drive aggregation, and aggregated peptide does not recover on thawing. A vial that has been frozen and thawed is not rescued by returning it to the fridge.
InsuranceTom said:Agreed, and light exposure is a real but secondary factor.
This is my experience too, for whatever a second data point is worth. The detail I would add is minor and it is already implied above.